Antithrombotic PreTreatment and Invasive Strategies in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome
Publication year
2020Source
Journal of Clinical Medicine, 9, 8, (2020), article 2578ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Cardiology
Journal title
Journal of Clinical Medicine
Volume
vol. 9
Issue
iss. 8
Subject
Radboudumc 16: Vascular damage RIHS: Radboud Institute for Health SciencesAbstract
In the current era, the antithrombotic treatment of patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) includes standard aspirin, and one of the potent P2Y12 inhibitors ticagrelor or prasugrel. The optimal timing of ticagrelor has not been adequately studied, while prasugrel is only recommended after coronary angiography prior to PCI. The invasive strategy, including indication and timing of angiography, depends on risk stratification and a mortality benefit has been shown in selected high-risk NSTE-ACS undergoing early (<24 h) intervention.
This item appears in the following Collection(s)
- Academic publications [227864]
- Electronic publications [107316]
- Faculty of Medical Sciences [86218]
- Open Access publications [76446]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.